Zuardi AW - Search Results

1

Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG. Crippa JAS, et al. Among authors: zuardi aw. Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):121-133. doi: 10.1007/s00406-019-00982-6. Epub 2019 Jan 31. Eur Arch Psychiatry Clin Neurosci. 2019. PMID: 30706171 Review.

2

Electrodermically nonresponsive schizophrenia patients make more errors in the Stroop Color Word Test, indicating selective attention deficit.

Lopes-Machado EZ, Crippa JA, Hallak JE, Guimarães FS, Zuardi AW. Lopes-Machado EZ, et al. Among authors: zuardi aw. Schizophr Bull. 2002;28(3):459-66. doi: 10.1093/oxfordjournals.schbul.a006953. Schizophr Bull. 2002. PMID: 12645677

3

Olanzapine for recurrent aggression in a patient with temporal lobe epilepsy who had temporal lobectomy.

Hallak JE, Dursun SM, Guarnieri R, Almeida E, Rezeck K, Crippa JA, Sakamoto AC, Zuardi AW, Deakin JF. Hallak JE, et al. Among authors: zuardi aw. J Psychopharmacol. 2003 Sep;17(3):350-1. doi: 10.1177/02698811030173020. J Psychopharmacol. 2003. PMID: 14513930

4

Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum.

Guimarães VM, Zuardi AW, Del Bel EA, Guimarães FS. Guimarães VM, et al. Among authors: zuardi aw. Life Sci. 2004 Jun 18;75(5):633-8. doi: 10.1016/j.lfs.2004.01.015. Life Sci. 2004. PMID: 15158372

5

Interictal SPECT in patients with mesial temporal lobe epilepsy and psychosis: a case-control study.

Guarnieri R, Wichert-Ana L, Hallak JE, Velasco TR, Walz R, Kato M, Alexandre V Jr, Terra-Bustamante VC, Bianchin MM, Zuardi AW, Deakin JF, Sakamoto AC. Guarnieri R, et al. Among authors: zuardi aw. Psychiatry Res. 2005 Jan 30;138(1):75-84. doi: 10.1016/j.pscychresns.2004.10.003. Psychiatry Res. 2005. PMID: 15708303

6

Electroconvulsive therapy for coexistent schizophrenia and obsessive-compulsive disorder.

Chaves MP, Crippa JA, Morais SL, Zuardi AW. Chaves MP, et al. Among authors: zuardi aw. J Clin Psychiatry. 2005 Apr;66(4):542-3. doi: 10.4088/jcp.v66n0420c. J Clin Psychiatry. 2005. PMID: 15816802 No abstract available.

7

Duloxetine in the treatment of panic disorder.

Crippa JA, Zuardi AW. Crippa JA, et al. Among authors: zuardi aw. Int J Neuropsychopharmacol. 2006 Oct;9(5):633-4. doi: 10.1017/S1461145705006206. Epub 2005 Nov 17. Int J Neuropsychopharmacol. 2006. PMID: 16288682 Free article. No abstract available.

8

Cannabidiol monotherapy for treatment-resistant schizophrenia.

Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA. Zuardi AW, et al. J Psychopharmacol. 2006 Sep;20(5):683-6. doi: 10.1177/0269881106060967. Epub 2006 Jan 9. J Psychopharmacol. 2006. PMID: 16401651 Clinical Trial.

9

Duloxetine in the treatment of social anxiety disorder.

Crippa JA, Filho AS, Freitas MC, Zuardi AW. Crippa JA, et al. Among authors: zuardi aw. J Clin Psychopharmacol. 2007 Jun;27(3):310. doi: 10.1097/01.jcp.0000270088.09415.6f. J Clin Psychopharmacol. 2007. PMID: 17502786 No abstract available.

10

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Zuardi AW. Zuardi AW. Braz J Psychiatry. 2008 Sep;30(3):271-80. doi: 10.1590/s1516-44462008000300015. Braz J Psychiatry. 2008. PMID: 18833429 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters